- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT02073240
Evaluation of an Enhanced Tuberculosis Infection Control Intervention in Healthcare Facilities in Vietnam and Thailand (EnTIC)
Study Design: Stratified, matched, cluster-randomized, controlled trial
Unit of Randomization: Healthcare facility
Study Duration: 3 years; prevalence of latent Tuberculosis infection (LTBI) in healthcare workers (HCWs) will be at measured at baseline, and LTBI incidence will be measured among susceptible HCWs at 12 and 24 months. Secondary outcomes will be measures at 0 (pre-intervention) 6, 12, 18, and 24 months. In year three, results will be analyzed and disseminated.
Study Components: Assessment of institutional safety culture; observations/audits of Tuberculosis (TB) patient flow (wait times) and HCW TB infection control (IC) practices; documentation of time intervals for processing sputum smears and initiation of TB treatment; facility assessments; random allocation and implementation of enhanced Tuberculosis infection control (TB IC) package; testing of HCWs to determine LTBI at 0, 12, 24 months; cost evaluation of intervention.
Sample Size: For the cluster randomized design, we estimate that 11 clusters per group will allow for 77 percent (%) power to identify a 30% reduction in LTBI incidence in the intervention vs. control clusters. This assumes LTBI incidence 5% per year in the control group, design effect for clustering of 2.0, and cluster size of 300 (average 600 HCW per cluster with 50% LTBI prevalence at baseline).
Study Overview
Status
Conditions
Intervention / Treatment
Detailed Description
TB remains a cause of substantial morbidity and mortality, affecting an estimated 13.7 million persons and resulting in 1.8 million deaths worldwide. TB transmission has been well-documented in a wide variety of healthcare settings. Moreover, the global expansion of HIV care programs may inadvertently increase TB transmission in healthcare settings by congregating highly susceptible individuals with those likely to have TB disease. The urgency of reducing TB transmission in healthcare facilities has been intensified by the emergence of drug-resistant TB strains, including extensively resistant TB strains, and the high mortality of these strains in people living with human immunodeficiency virus (HIV).
Healthcare workers are at higher risk of both TB infection and disease compared to the general population, with estimates that 63-94% of TB infection and up to 89% of TB disease in this population is due to occupational exposure.
The World Health Organization (WHO) has identified institutional TB IC as one of the core "3 I's" interventions required to reduce the burden of TB among people living with HIV. Although TB IC guidelines exist and a "package" of interventions has been shown to successfully interrupt TB outbreaks in U.S. hospitals, there is limited information on feasibility, impact or cost of TB IC programs in middle- and low-income countries where TB burdens are high and nosocomial TB transmission has been well-documented.
Currently recommended TB IC strategies are complex and multi-faceted and include: administrative controls (e.g., early identification, treatment, and isolation or cohorting of infectious TB patients); effective engineering/environmental controls (such as, general ventilation or ultraviolet germicidal irradiation); and appropriate use of respiratory protection (N-95 particulate respirators) to protect HCWs. Implementation of many of these recommended measures require administrative/managerial support and sustained behavior change of frontline staff; some require substantial healthcare expenditures. There is an urgent need for simple, evidence-based and cost-effective strategies to help guide implementation of TB IC programs and reduce institutional TB transmission in resource-limited settings where TB and HIV are endemic. A recent call to address gaps in the TB IC evidence base identified key priorities including operational research to investigate the efficacy and cost-effectiveness of TB IC measures, and behavioral research to develop effective strategies to inform, motivate and provide skills to HCWs to implement and sustain effective airborne IC procedures and practices. This study directly addresses these identified priorities.
At root, ensuring good implementation of all TB IC procedures is a challenge of HCW behavior change. Even appropriate use of simple environmental control measures, requires a substantial element of behavior change to ensure effectiveness; for example, keeping needed windows open, ensuring needed fans are on and directed appropriately, and ensuring performance of routine maintenance checks of equipment. In this evaluation, the proposed intervention package focuses on tools and techniques that support the development of an institutional culture of safety and HCW behavior change regarding TB IC practices.
The theoretical framework for this intervention package is based on evidence showing that certain interventions favorably impact HCWs' IC practices and related patient outcomes, specifically 1) audits and feedback of IC performance and outcome data, 2) participation in IC collaborative (including mentoring), and 3) use of standardized IC checklists. Audit and feedback of performance have been used for decades as a strategy to improve implementation and adherence to clinical practice guidelines. Performance feedback has similarly been shown to be an effective intervention for improving IC practices. Also, there is a growing body of evidence to support the use of simple, evidence-based checklists as an effective IC strategy. When studied, use of checklists has fostered adoption of best practices, resulting in significant and sustained reductions in the targeted healthcare-associated infections (such as, surgical site infections and catheter-related bloodstream infections). Checklists are intended to be practical, easy-to-use tools that are designed to improve recall, prompt providers to perform recommended infection prevention steps, and make clear minimum expectations for IC. While the checklist approach has been used widely in other aspects of hospital IC, it has not yet been used widely for airborne IC. Lastly, collaboratives have been used to address a variety of health care issues and when studied in randomized trials, their efficacy has ranged from -16% to 70%. In Thailand, IC collaboratives have been associated with lower rates of healthcare-associated infections and better IC practices. In this study, we propose to use a robust study design to implement a multi-faceted TB IC package and to assess the impact of its implementation on TB transmission in hospitals and clinics where care is provided to patients with TB or other potential airborne respiratory infections.
Study Type
Enrollment (Actual)
Contacts and Locations
Study Locations
-
-
Cha Cherng Sao
-
Maruphong, Cha Cherng Sao, Thailand
- Buddhasothorn Hospital
-
-
Chaiyaphum
-
Nai Mueang, Chaiyaphum, Thailand, 36000
- Chaiyaphum Hosptial
-
-
Changwat Ratchaburi
-
Banpong, Changwat Ratchaburi, Thailand, 70110
- Banpong Hospital
-
-
Chumpon
-
Mueang, Chumpon, Thailand
- Chumponkhetudomsak Hospital
-
-
Nakhonnayok
-
Mueang Nakhonnayok, Nakhonnayok, Thailand, 26000
- Nakhon Nayok Hospital
-
-
Nan
-
Nai Wiang, Mueang Nan, Nan, Thailand, 55000
- Nan Hospital
-
-
Pichit
-
Nai Mueang, Pichit, Thailand, 66000
- Pichit Hospital
-
-
Prachinburi
-
Mueang Prachinburi, Prachinburi, Thailand, 25000
- Chao Phraya Abhaibhubejhr Hosptial
-
-
Praputtabat
-
Saraburi, Praputtabat, Thailand
- Praputtabat Hosptial
-
-
Singburi
-
Mueang Singburi, Singburi, Thailand, 16000
- Singburi Hospital
-
-
-
-
-
Binh Phuoc, Vietnam
- Binh Phuoc General Hospital
-
Dong Nai, Vietnam
- Dong Nai TB Hospital
-
Dong Thap, Vietnam
- Dong Thap TB Hospial
-
Hai Duong, Vietnam
- Hai Duong TB Hospital
-
Hoa Binh, Vietnam
- Hoa Binh General Hospital
-
Hung Yen, Vietnam
- Hung Yen Provincial Hospital
-
Long An, Vietnam
- Long An General Hospital
-
Nam Dinh, Vietnam
- Nam Dinh General Hospital
-
Quang Ninh, Vietnam
- Quang Ninh TB Hospital
-
Tien Giang, Vietnam
- Tien Giang General Hospital
-
Vinh Long, Vietnam
- Vinh Long General Hosptial
-
Vinh Phuc, Vietnam
- Vinh Phuc General Hospital
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Sampling Method
Study Population
Description
Inclusion Criteria:
- General provincial or regional hospital of at least 300 beds OR
- TB or Respiratory hospitals of at least 100 beds
- Geographic location that allows for ground transport of blood specimens to a designated reference laboratory within 16 hours of blood draw
- Hospital director is willing to commit staff time to study participation, including designating personnel to oversee TB IC and EnTIC study activities, as evidenced by a letter of support for the study
Exclusion Criteria:
- Specialty hospitals (such as, pediatric, infectious diseases, maternity)
- Recent (within the past 3 years) or current participation in a TB IC initiative
Study Plan
How is the study designed?
Design Details
- Observational Models: Other
- Time Perspectives: Prospective
Cohorts and Interventions
Group / Cohort |
Intervention / Treatment |
|---|---|
|
Enhanced TB IC Package
Facilities randomized to the intervention group will receive the following:
|
Facilities randomized to the intervention group will receive:
|
|
Usual Care Group
Usual Care group will receive available TB IC training/education alone.
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Change in prevalence and incidence of latent Tuberculosis infection in healthcare workers
Time Frame: 0 months, 12 months, 24 months
|
Measured by an interferon gamma release assay, QuantiFERON-TB Gold In-Tube
|
0 months, 12 months, 24 months
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Change in institutional safety culture
Time Frame: 0 months and 24 months
|
Measured by the Hospital Survey on Patient Safety
|
0 months and 24 months
|
|
Adherence to recommended TB Infection Control practices
Time Frame: 0 months, 6 months, 12 months, 18 months, 24 months
|
Measured by observation of healthcare worker-patient encounters, turn-around-times, wait times, and time-to-treatment
|
0 months, 6 months, 12 months, 18 months, 24 months
|
Other Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Cost data
Time Frame: 0 months, 6 months, 12 months, 18 months, 24 months
|
Measured by collecting costs associated with infection control
|
0 months, 6 months, 12 months, 18 months, 24 months
|
Collaborators and Investigators
Collaborators
Investigators
- Principal Investigator: Michele L Pearson, MD, Centers for Disease Control and Prevention, Center for Global Health, Division of Global HIV and TB
- Principal Investigator: Sara J Whitehead, MD, Centers for Disease Control and Prevention
Study record dates
Study Major Dates
Study Start (Actual)
Primary Completion (Actual)
Study Completion (Actual)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Estimate)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
Other Study ID Numbers
- CDC-DTBE-6498
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Tuberculosis
-
Global Alliance for TB Drug DevelopmentCompletedTuberculosis | Tuberculosis, Pulmonary | Pulmonary Disease | Multi Drug Resistant Tuberculosis | Drug Sensitive Tuberculosis | Drug-resistant Tuberculosis | Mycobacterium Tuberculosis InfectionUnited States
-
Global Alliance for TB Drug DevelopmentCompletedTuberculosis | Tuberculosis, Pulmonary | Pulmonary Disease | Multi Drug Resistant Tuberculosis | Drug Sensitive Tuberculosis | Drug-resistant Tuberculosis | Mycobacterium Tuberculosis InfectionUnited States
-
Beijing Chest HospitalHuashan Hospital; National Medical Center for Infectious DiseasesNot yet recruitingTuberculosis | Drug-resistant Tuberculosis | Pulmonary Tuberculosis | Rifampicin Resistant TuberculosisChina
-
Universiteit AntwerpenAurum Institute; University of Stellenbosch; University of the Free State; Free...RecruitingDrug-resistant Tuberculosis | Rifampicin Resistant Tuberculosis | Pulmonary Tuberculoses | Multidrug Resistant TuberculosisSouth Africa
-
Assistance Publique - Hôpitaux de ParisCompletedExtrapulmonary Tuberculosis | Lymph Node Tuberculosis | Bone TuberculosisFrance
-
Centers for Disease Control and PreventionBoston University; Pfizer; Columbia University; University of Texas; University of... and other collaboratorsCompletedMulti-Drug Resistant Tuberculosis | Extensively Drug Resistant TuberculosisSouth Africa
-
University of Cape TownUniversity of Stellenbosch; University of Cape Town Lung Institute; University... and other collaboratorsCompletedTuberculosis | Multidrug Resistant Tuberculosis | Extensively-drug Resistant TuberculosisSouth Africa
-
Huashan HospitalThe Hong Kong Polytechnic UniversityNot yet recruitingPulmonary Tuberculosis | Tuberculosis (TB) | Tuberculosis ActiveChina
-
Shandong UniversityShandong Public Health Clinical CenterNot yet recruiting
-
Huashan HospitalBeijing Chest HospitalActive, not recruitingDrug-resistant Tuberculosis | Pulmonary Tuberculosis | Rifampin-resistant TuberculosisChina
Clinical Trials on Enhanced TB IC Package
-
University of North Carolina, Chapel HillNational Institute of Mental Health (NIMH)CompletedHuman Immunodeficiency VirusMalawi
-
Management Sciences for HealthKNCV Tuberculosis FoundationRecruiting
-
University of North Carolina, Chapel HillNational Institute of Mental Health (NIMH); Kamuzu University of Health Sciences and other collaboratorsCompleted
-
Elizabeth Glaser Pediatric AIDS FoundationBill and Melinda Gates FoundationActive, not recruitingAIDS-related Kaposi Sarcoma | Cryptococcal Infections | AIDS and Infections | Opportunistic Infections, HIV-Related | AIDS With TuberculosisMalawi
-
Medical University of South CarolinaNational Institutes of Health (NIH)Not yet recruitingPrevention | Maltreatment | Parenting Intervention
-
WestatMakerere UniversityCompleted
-
Columbia UniversityNational Institute on Drug Abuse (NIDA)CompletedSubstance Abuse, Intravenous | Human Immunodeficiency VirusUnited States, Kazakhstan
-
University of North Carolina, Chapel HillCenters for Disease Control and Prevention; Centre for Infectious Disease Research...Completed
-
Ming YangRecruitingCentral Nervous System Tumor | Surgical Site Infection (SSI)China
-
LanZhou UniversityNot yet recruitingColonoscopy | Bowel Preparation | Quality of HealthcareChina